Abstract
With a growing elderly population, the incidence of osteoporotic fractures will increase over the coming decades. In old age, osteoporotic fractures are associated with a substantial burden in terms of morbidity and mortality and higher costs for society compared with fractures in younger individuals.
Nevertheless, osteoporosis in old age continues to be underdiagnosed and undertreated. Multiple competing factors: frailty, comorbidities, falls, polypharmacy and drug interactions, and other factors influence our approach to fracture prevention in this population.
Most studies show continued efficacy of pharmacologic interventions in age group >= 75-80 years, although they are largely limited by small sample sizes. We herein review the available evidence of pharmacologic interventions for fracture risk reduction in this population.